Johanna Ungerstedt

Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.
Kynning MK, Westerberg E, Forsell L, Creignou M, Berggren DM, Tesi B, Bernard E, Papaemmanuil E, Nannya Y, Franco LC, Valentini D, Lindberg EH, Ogawa S, Ejerblad E, Ungerstedt J.
Br J Haematol. 2025 Nov 25. doi: 10.1111/bjh.70264. PMID: 41287892

No indication of aberrant neutrophil extracellular trap release in indolent or advanced systemic mastocytosis.
Rosell A, Karlström C, Dahlin JS, Boey D, Klimkowska M, Ax K, Thålin C, Ungerstedt J.
Scand J Immunol. 2024 Jan;99(1):e13333. PMID: 38112220

Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis.
Söderlund S, Boey D, van Midden W, Kjellander M, Ax K, Qian H, Dahlin JS, Ungerstedt J.
J Allergy Clin Immunol. 2023 Jul;152(1):205-213. PMID: 36813186

Omalizumab alleviates pruritus in myeloproliferative neoplasms.
Ravn Landtblom A, Ungerstedt J, Hedlund A, Tobiasson M, Deneberg S, Jädersten M. Haematologica.
2023 Jul 1;108(7):1968-1971. PMID: 36700402

Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience.
Ungerstedt J, Ljung C, Klimkowska M, Gülen T.Cancers (Basel).
2022 Aug 16;14(16):3942-48. PMID: 36010937

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Moreno Berggren D, Kjellander M, Backlund E, Engvall M, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ungerstedt J, Ejerblad E.
Br J Haematol. 2021 Feb;192(3):474-483. PMID: 32501529